Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models

Among the plethora of cancer immune evasion mechanisms, T-cell-inhibiting factors within the tumor microenvironment impose a major challenge for the development of novel immunotherapies. Strategies to overcome immunosuppression and remodel the TME are therefore urgently needed. Therapeutic cancer va...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kimberly Pojar, Diana Reckendorfer, Judith Strauss, Sarah Szaffich, Sarah Ahmadi-Erber, Timo Schippers, Pedro Berraondo, Klaus K. Orlinger, Josipa Raguz, Henning Lauterbach
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Taylor & Francis Group 2025-12-01
Saila:	OncoImmunology
Gaiak:	Arenavirus vectors artLCMV cancer immunotherapy cancer vaccine IL-12 intratumoral virotherapy
Sarrera elektronikoa:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2514040
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!